Dystrophin immunity in Duchenne's muscular dystrophy

New England Journal of Medicine

Volumn 363, Issue 15, 2010, Pages 1429-1437

  Mendell, Jerry R ^a,b   Campbell, Katherine ^a,b   Rodino Klapac, Louise ^a,b   Sahenk, Zarife ^a,b   Shilling, Chris ^a   Lewis, Sarah ^a   Bowles, Dawn ^c   Gray, Steven ^c   Li, Chengwen ^c   Galloway, Gloria ^a   Malik, Vinod ^a   Coley, Brian ^a   Clark, K Reed ^a   Li, Juan ^d   Xiao, Xiao ^d   Samulski, Jade ^e   McPhee, Scott W ^e   Samulski, R Jude ^c   Walker, Christopher M ^a,b  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e ASKLEPIOS BIOPHARMACEUTICAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DEFLAZACORT; DYSTROPHIN; METHYLPREDNISOLONE; AUTOANTIBODY; VIRUS DNA;

ADENO ASSOCIATED VIRUS; ARTICLE; BICEPS BRACHII MUSCLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; DUCHENNE MUSCULAR DYSTROPHY; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; LOW DRUG DOSE; MALE; MYCOSIS; NAUSEA; PRIORITY JOURNAL; RASH; SORE THROAT; STOMACH DISCOMFORT; T LYMPHOCYTE; TRANSGENE; VIRAL GENE THERAPY; AUTOIMMUNITY; CHEMISTRY; CHILD; DEPENDOPARVOVIRUS; FRAMESHIFT MUTATION; GENE THERAPY; GENE VECTOR; GENETICS; IMMUNOLOGY; MUSCULAR DYSTROPHY, DUCHENNE; PROTEIN SYNTHESIS; SKELETAL MUSCLE;

AUTOANTIBODIES; AUTOIMMUNITY; CHILD; DEPENDOVIRUS; DNA, VIRAL; DYSTROPHIN; FRAMESHIFT MUTATION; GENETIC THERAPY; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; MALE; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; PROTEIN BIOSYNTHESIS; T-LYMPHOCYTES; TRANSGENES;

EID: 77957725001     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1000228     Document Type: Article

References (24)

1. Emery AE. The muscular dystrophies. Lancet 2002;359:687-95.
2. Gregorevic P, Allen JM, Minami E, et al. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med 2006;12:787-9. (Pubitemid 44050067)
3. Fabb SA, Wells DJ, Serpente P, Dickson G. Adeno-associated virus vector gene transfer and sarcolemmal expression of a 144 kDa micro-dystrophin effectively restores the dystrophin-associated protein complex and inhibits myofibre degeneration in nude/mdx mice. Hum Mol Genet 2002;11:733-41.
4. Wang B, Li J, Xiao X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci U S A 2000;97:13714-9.
5. Mendell JR, Moxley RT, Griggs RC, et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 1989;320:1592-7.
6. Angelini C. The role of corticosteroids in muscular dystrophy: a critical appraisal. Muscle Nerve 2007;36:424-35. (Pubitemid 47512066)
7. Klein CJ, Coovert DD, Bulman DE, Ray PN, Mendell JR, Burghes AH. Somatic reversion/suppression in Duchenne muscular dystrophy (DMD): evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers. Am J Hum Genet 1992;50:950-9.
8. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006;12:342-7.
9. Mingozzi F, Maus MV, Hui DJ, et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 2007;13:419-22. (Pubitemid 46559826)
10. Mingozzi F, Meulenberg JJ, Hui DJ, et al. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood 2009;114:2077-86.
11. Brantly ML, Chulay JD, Wang L, et al. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci U S A 2009;106:16363-8. [Erratum, Proc Natl Acad Sci U S A 2009;106:17606.]
12. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008;358:2231-9.
13. Cideciyan AV, Aleman TS, Boye SL, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A 2008;105:15112-7.
14. Hauswirth WW, Aleman TS, Kaushal S, et al. Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 2008;19:979-80.
15. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008;358:2240-8.
16. Mendell JR, Rodino-Klapac LR, Rosales- Quintero X, et al. Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins. Ann Neurol 2009;66:290-7.
17. Maguire AM, High KA, Auricchio A, et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 2009;374:1597-605. [Erratum, Lancet 2010;375:30.]
18. Gussoni E, Pavlath GK, Miller RG, et al. Specific T cell receptor gene rearrangements at the site of muscle degeneration in Duchenne muscular dystrophy. J Immunol 1994;153:4798-805.
19. Mantegazza R, Andreetta F, Bernasconi P, et al. Analysis of T cell receptor repertoire of muscle-infiltrating T lymphocytes in polymyositis: restricted V alpha/ beta rearrangements may indicate antigen- driven selection. J Clin Invest 1993; 91:2880-6.
20. Ferrer A, Wells KE, Wells DJ. Immune responses to dystropin: implications for gene therapy of Duchenne muscular dystrophy. Gene Ther 2000;7:1439-46.
21. Wells DJ, Ferrer A, Wells KE. Immunological hurdles in the path to gene therapy for Duchenne muscular dystrophy. Expert Rev Mol Med 2002;4:1-23.
22. Harkiolaki M, Holmes SL, Svendsen P, et al. T cell-mediated autoimmune disease due to low-affinity crossreactivity to common microbial peptides. Immunity 2009; 30:348-57. [Erratum, Immunity 2009;30: 610.]
23. van Deutekom JC, Janson AA, Ginjaar IB, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007;357:2677-86.
24. Muntoni F, Wells D. Genetic treatments in muscular dystrophies. Curr Opin Neurol 2007;20:590-4.